Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
222 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | terminated | Phase 1 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2022 |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | terminated | Phase 1 | 16 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 11, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02207504 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03136640 | ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 23 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT01646684 | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT03774056 | A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | completed | Phase 1 | 43 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03778047 | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | completed | Phase 1 | 10 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03137758 | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 12 | Pellficure Pharmaceuticals, IncINDUSTRY | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02991911 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer(MEDI3726) | completed | Phase 1 | 33 | MedImmune LLCINDUSTRY | 3 | Jan 18, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT00868595 | MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | completed | Phase 1 | 18 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT03030885 | Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02532114 | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | completed | Phase 1 | 5 | University of WashingtonOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02705469 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 44 | Zenith EpigeneticsINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01594918 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 25 | Rahul AggarwalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT03074032 | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 17 | Avionco LLCINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT02396368 | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer(Radium-223) | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT02502994 | Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC | unknown | Phase 1 | 12 | Norio NonomuraOTHER | 1 | Jul 20, 2015 | clinicaltrials |
| NCT01610050 | A Phase I Study of LFA102 in Japanese Patients | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 11, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01911741 | A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects | completed | Phase 1 | 55 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jul 30, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 5, 2022source: clinicaltrials